TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AEON Biopharma ( (AEON) ) has shared an update.
On June 13, 2025, AEON Biopharma, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Jost Fischer and Eric Carter as Class II directors for a three-year term, and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (AEON) stock is a Buy with a $432.00 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.
Spark’s Take on AEON Stock
According to Spark, TipRanks’ AI Analyst, AEON is a Underperform.
AEON Biopharma is under significant financial distress, with negative profitability and cash flow challenges. While technical indicators show some stabilization, the overall bearish trend persists. The lack of profitability and absence of dividends weigh heavily on its valuation. The neutral earnings call impact slightly offsets these negatives but is insufficient to improve the overall outlook.
To see Spark’s full report on AEON stock, click here.
More about AEON Biopharma
AEON Biopharma, Inc. operates in the biopharmaceutical industry, focusing on developing therapeutic treatments.
Average Trading Volume: 953,733
Technical Sentiment Signal: Sell
Current Market Cap: $10.92M
For an in-depth examination of AEON stock, go to TipRanks’ Overview page.